On July 8, 2025, Evercore ISI Group maintained its "Outperform" rating for Jasper Therapeutics (JSPR, Financial) while significantly lowering the price target for the company's stock. The updated price target is set at $20.00 USD, a 60% decrease from the prior target of $50.00 USD.
Analyst Gavin Clark-Gartner from Evercore ISI Group is responsible for the revised price target, reflecting a notable shift in expectations for JSPR's stock performance. Despite the reduction in price target, the maintained "Outperform" rating indicates continued confidence in Jasper Therapeutics' long-term prospects.
Jasper Therapeutics (JSPR, Financial) remains listed on the NASDAQ exchange with this latest update impacting investor outlooks. As of now, stakeholders and potential investors may need to reassess their positions in light of these new developments.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Jasper Therapeutics Inc (JSPR, Financial) is $29.13 with a high estimate of $70.00 and a low estimate of $4.00. The average target implies an upside of 858.06% from the current price of $3.04. More detailed estimate data can be found on the Jasper Therapeutics Inc (JSPR) Forecast page.
Based on the consensus recommendation from 11 brokerage firms, Jasper Therapeutics Inc's (JSPR, Financial) average brokerage recommendation is currently 2.2, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
